OpenNashEarnings

Zimmer Biomet (ZBH) · Medical Devices

Zimmer Biomet Q3 2026 earnings: summary, key numbers & outlook

Results filed 4 Nov 2026 · Quarter ended 30 Sep 2026

Press release ↗Investor relations ↗

Summaries and transcripts are machine-generated and can contain errors.

In brief

Zimmer Biomet says its diversification strategy is working, as Hips, S.E.T. and Technology & Data grew at upper single or double digits while Knees shrank, and it extended its THINK Surgical robotics deal.

Zimmer Biomet's growth is shifting away from knees. Hips, S.E.T. and Technology & Data, Bone Cement and Surgical grew at upper single-digit or double-digit rates and together make up two-thirds of the business, while Knees declined in both the U.S. and internationally. The company extended its multi-year distribution and supply agreement with THINK Surgical, launched foot and ankle products, and opened a surgeon training facility in Charlotte.

Management is steering toward a broader portfolio, a more comprehensive robotics offering and a reshaped U.S. commercial organization, backed by leadership promotions. It raised its full-year organic growth outlook on this momentum. The main tension is that Knees, the largest category, is still shrinking, and the U.S. sales and distribution transformation and the portfolio rationalization both carry execution risk.

Key numbers

Net sales · GAAP
$2.063 billion

increased 3.1% on a reported basis and 3.7% on a constant currency basis

Net earnings · GAAP
$191.6 million

Diluted EPS · GAAP
$1.00

a decrease of 13.8%

Adjusted diluted EPS · non-GAAP
$1.90

consistent with the prior year period

Gross margin · GAAP
63.1%

Operating profit · GAAP
$307.6M

Operating profit margin · GAAP
14.9%

Operating cash flow · GAAP
$560.0 million

Segment or metricValueChange
Knees$767.5M(3.1)% reported, (2.6)% constant currency
Hips$536.5M6.0% reported, 7.0% constant currency
S.E.T.$578.3M6.8% reported, 7.1% constant currency
Technology & Data, Bone Cement and Surgical$180.6M11.9% reported, 13.0% constant currency
United States$1.2B3.6% reported and constant currency
International$857.2M2.4% reported, 3.9% constant currency
Where each number comes from
  • Net sales: “Third quarter net sales of $2.063 billion increased 3.1% on a reported basis and 3.7% on a constant currency1 basis”
  • Net earnings: “Net earnings for the third quarter were $191.6 million, or $362.8 million on an adjusted1 basis.”
  • Diluted EPS: “Diluted earnings per share were $1.00 for the third quarter, a decrease of 13.8%, and adjusted1 diluted earnings per share were $1.90”
  • Adjusted diluted EPS: “adjusted1 diluted earnings per share were $1.90, consistent with the prior year period.”
  • Gross margin: “Gross margin | 63.1% | 63.2% | 63.7% | 63.4%”
  • Operating profit: “Operating Profit | 307.6 | 351.3”
  • Operating profit margin: “Operating profit margin | 14.9% | 17.6% | 15.9% | 15.8%”
  • Operating cash flow: “Zimmer Biomet generated $560.0 million in operating cash flow and $372.4 million of free cash flow1 in the third quarter.”
  • Knees: “Total | 767.5 | (3.1) | (2.6) Hips United States | 280.1 | 5.8 | 5.8”
  • Hips: “Total | 536.5 | 6.0 | 7.0 S.E.T. * | 578.3 | 6.8 | 7.1”
  • S.E.T.: “Total | 536.5 | 6.0 | 7.0 S.E.T. * | 578.3 | 6.8 | 7.1”
  • Technology & Data, Bone Cement and Surgical: “Technology & Data, Bone Cement and Surgical | 180.6 | 11.9 | 13.0”
  • United States: “United States | $1,205.6 | 3.6% | 3.6% International | 857.2 | 2.4 | 3.9”
  • International: “United States | $1,205.6 | 3.6% | 3.6% International | 857.2 | 2.4 | 3.9”

Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.

From the filingQ3 2026vs year agovs last quarter
Revenue$2.1B+3.1%−5.2%
Operating income$307.6M−12.4%−5.7%
Net income$191.6M−17.0%−3.4%
Diluted EPS$1.00−13.8%−2.9%
Free cash flow$484.2M+33.1%+23.0%
Operating margin14.9%−2.7 pts−0.1 pts

Calculated by code from XBRL, not by the model.

Outlook

MetricPeriodOutlook
Reported revenue changeyear ending December 31, 20264.4% - 4.9%
Constant currency revenue changeyear ending December 31, 20264.1% - 4.6%
Organic constant currency revenue changeyear ending December 31, 20263.0% - 3.5%
Foreign currency exchange impactyear ending December 31, 2026+0.25%
Adjusted diluted EPSyear ending December 31, 2026$8.50- $8.60

Key takeaways

  1. Diversification beyond knees is showing results

    Hips, S.E.T. and Technology & Data, Bone Cement and Surgical grew at upper single-digit or double-digit rates and represent two-thirds of the book of business. Management says this validates its diversification strategy.

  2. Knees remain the drag on growth

    Knees sales fell 3.1% reported and 2.6% in constant currency, declining in both the U.S. and internationally. As the largest category, it still holds back overall growth.

  3. Robotics partnership with THINK Surgical extended

    Zimmer Biomet extended a multi-year limited exclusive distribution and supply agreement with THINK Surgical. It says this reinforces its aim of offering the most comprehensive robotics portfolio.

  4. Foot and ankle portfolio expanded with two launches

    The company launched the Megalodon Dynamic Compression System and SmartShot Marrow Access Device. This builds on the faster-growing S.E.T. franchise, which grew 7.1% in constant currency.

  5. U.S. commercial transformation and surgeon education investments

    Three leaders were promoted to accelerate the U.S. commercial transformation, and a new Zimmer Biomet Institute facility opened in Charlotte covering robotics and AI-enabled technologies. Management cites commercial execution as a driver of results.

Charts

Revenue$2.1B+3.1% y/yQ3 2026
Q4 2024: $2.0B (worked out from the annual figure)Q4 ’24$2.0BQ1 2025: $1.9BQ1 ’25$1.9BQ2 2025: $2.1BQ2 ’25$2.1BQ3 2025: $2.0BQ3 ’25$2.0BQ4 2025: $2.2B (worked out from the annual figure)Q4 ’25$2.2BQ1 2026: $2.1BQ1 ’26$2.1BQ2 2026: $2.2BQ2 ’26$2.2BQ3 2026: $2.1BQ3 ’26$2.1B

Fourth quarter worked out from the annual figure.

Data
Q4 2024$2.0B *
Q1 2025$1.9B
Q2 2025$2.1B
Q3 2025$2.0B
Q4 2025$2.2B *
Q1 2026$2.1B
Q2 2026$2.2B
Q3 2026$2.1B
Diluted EPS (GAAP)$1.00−13.8% y/yQ3 2026
Q1 2025: $0.91Q1 ’25$0.91Q2 2025: $0.77Q2 ’25$0.77Q3 2025: $1.16Q3 ’25$1.16Q1 2026: $1.22Q1 ’26$1.22Q2 2026: $1.03Q2 ’26$1.03Q3 2026: $1.00Q3 ’26$1.00
Data
Q1 2025$0.91
Q2 2025$0.77
Q3 2025$1.16
Q1 2026$1.22
Q2 2026$1.03
Q3 2026$1.00

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin14.9%−2.7 pts y/yQ3 2026
Q4 2024: 19.2%Q4 ’2419.2%Q1 2025: 15.3%Q1 ’2515.3%Q2 2025: 14.4%Q2 ’2514.4%Q3 2025: 17.6%Q3 ’2517.6%Q4 2025: 6.9%Q4 ’256.9%Q1 2026: 17.9%Q1 ’2617.9%Q2 2026: 15.0%Q2 ’2615.0%Q3 2026: 14.9%Q3 ’2614.9%
Data
Q4 202419.2%
Q1 202515.3%
Q2 202514.4%
Q3 202517.6%
Q4 20256.9%
Q1 202617.9%
Q2 202615.0%
Q3 202614.9%
Free cash flow$484.2M+33.1% y/yQ3 2026
Q4 2024: $454.8MQ4 ’24$454.8MQ1 2025: $338.2MQ1 ’25$338.2MQ2 2025: $328.1MQ2 ’25$328.1MQ3 2025: $363.7MQ3 ’25$363.7MQ4 2025: $442.6MQ4 ’25$442.6MQ1 2026: $323.1MQ1 ’26$323.1MQ2 2026: $393.6MQ2 ’26$393.6MQ3 2026: $484.2MQ3 ’26$484.2M
Data
Q4 2024$454.8M
Q1 2025$338.2M
Q2 2025$328.1M
Q3 2025$363.7M
Q4 2025$442.6M
Q1 2026$323.1M
Q2 2026$393.6M
Q3 2026$484.2M

Operating cash flow minus capital expenditure, from cash flow statements.

Questions

Where is Zimmer Biomet's growth coming from?

Hips, S.E.T. and Technology & Data, Bone Cement and Surgical grew at upper single-digit or double-digit rates and make up two-thirds of its book of business. Technology & Data, Bone Cement and Surgical grew fastest at 13.0% in constant currency.

How are knees performing?

Knees sales declined 3.1% reported and 2.6% in constant currency in the quarter. Both the U.S. (down 2.0%) and international (down 3.4% constant currency) fell.

What is Zimmer Biomet doing in robotics?

It extended a multi-year limited exclusive distribution and supply agreement with THINK Surgical. The company says this supports offering the most comprehensive robotics portfolio.

What new products did the company launch?

It launched the Megalodon Dynamic Compression System and SmartShot Marrow Access Device, expanding its foot and ankle portfolio.

How did management change its 2026 outlook?

It raised full-year organic constant-currency growth guidance to 3.0% - 3.5% from 2.25% - 3.25%. It also raised adjusted EPS guidance to $8.50- $8.60 from $8.47 - $8.59.

Documents

SEC filing

Call recording

Call recording on YouTube ↗. Official replay ↗.